# EDGAR Filing Document

**Accession Number:** 0002115025
**File Stem:** 0001193125-26-145520
**Filing Date:** 2026-4
**Character Count:** 11116
**Document Hash:** 37857309ec0b64bab788af740bf16d09
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-145520.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0001193125-26-145520

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260403

**FILED AS OF DATE**: 20260407

**DATE AS OF CHANGE**: 20260407

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bowen Matthew
- **CENTRAL INDEX KEY:** 0002115025

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40522
- **FILM NUMBER:** 26844715

**MAIL ADDRESS:**
- **STREET 1:** MONTE ROSA THERAPEUTICS, INC.
- **STREET 2:** 321 HARRISON AVENUE, SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Monte Rosa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001826457
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **STREET 2:** SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** 617-949-2643

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **STREET 2:** SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118

## Ex-24

**LIMITED POWER OF ATTORNEY**

The undersigned hereby constitutes and appoints each of Markus Warmuth and Phil Nickson, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of **Monte Rosa Therapeutics, Inc.** (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;

(2)do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and

(3)take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in- fact ceases to be an employee of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 7, 2026.

<u>/s/ Matthew Bowen</u> 

Signature

<u>Matthew Bowen</u> 

Print Name

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bowen Matthew<br><sub>(Last) (First) (Middle)</sub><br>MONTE ROSA THERAPEUTICS, INC.<br>321 HARRISON AVENUE, SUITE 900<br><sub>(Street)</sub><br>BOSTON, MA 02118<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Monte Rosa Therapeutics, Inc. [ GLUE ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-04-03 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Principal Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 21604<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2031-10-31 | Common Stock | 5500 | $23.99 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2032-02-29 | Common Stock | 9950 | $13.41 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2033-01-02 | Common Stock | 3551 | $7.78 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2034-01-01 | Common Stock | 3698 | $5.71 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2034-02-28 | Common Stock | 1501 | $6.3 | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2035-01-01 | Common Stock | 10800 | $7.11 | D |  |
| Stock Option (Right to Buy) | <sup>(7)</sup> | 2035-09-30 | Common Stock | 625 | $7.5 | D |  |
| Stock Option (Right to Buy) | <sup>(8)</sup> | 2036-01-01 | Common Stock | 7400 | $15.31 | D |  |

---

### Footnotes:

(1) The amount reported in Column 2 includes 3,590 unvested restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement.

(2) This option is fully vested and exercisable.

(3) 25% of this option vested and became exercisable on January 3, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(4) 25% of this option vested and became exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(5) 25% of this option vested and became exercisable on March 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(6) 25% of this option vested and became exercisable on January 2, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(7) 25% of this option shall vest and become exercisable on October 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(8) 25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Phil Nickson, Attorney-in-Fact  
**Date:** 2026-04-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**